11 Mar 2019 09:48
PDMR Dealing
LONDON, March 11, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 8, 2019, Dr. David Ebsworth, Chairman of the Company, purchased a further 17,500 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 57 pence per Ordinary Share and a total purchase price of £9,975.00. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 235,387 Ordinary Shares, representing 0.22% of the Company’s issued share capital.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | David Ebsworth | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chairman | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Verona Pharma plc | |
| b) | LEI | 213800EVI6O6J3TIAL06 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrumentIdentification code | Ordinary Shares of 5 pence eachGB00BYW2KH80 | |
| b) | Nature of the transaction | David Ebsworth purchased 17,500 Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 57 pence per Ordinary Share | 17,500 Ordinary Shares | ||
| d) | Aggregated information Aggregated volumePrice | N/A | |
| e) | Date of the transaction | 8 March 2019 | |
| f) | Place of the transaction | London Stock Exchange, AIM | |
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive OfficerVictoria Stewart, Director of Communications | info@veronapharma.com |
| Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) | Tel: +44 (0) 20 7710 7600 |
| Stewart Wallace / Jonathan Senior / Ben Maddison |